{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:57:30Z","timestamp":1793912250560,"version":"4.8.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170301"],"award-info":[{"award-number":["RP170301"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13046-017-0578-1","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T11:17:13Z","timestamp":1502450233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials"],"prefix":"10.1186","volume":"36","author":[{"given":"Andrew S.","family":"Gdowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalendu","family":"Ranjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamboor K.","family":"Vishwanatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,11]]},"reference":[{"key":"578_CR1","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.drudis.2014.08.007","volume":"19","author":"MS Kinch","year":"2014","unstructured":"Kinch MS. An analysis of FDA-approved drugs for oncology. Drug Discov Today. 2014;19:1831\u20135.","journal-title":"Drug Discov Today"},{"key":"578_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"578_CR3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"578_CR4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","volume":"3","author":"IJ Fidler","year":"2003","unstructured":"Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453\u20138.","journal-title":"Nat Rev Cancer"},{"key":"578_CR5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10238-006-0117-4","volume":"6","author":"D Ribatti","year":"2006","unstructured":"Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clin Exp Med. 2006;6:145\u20139.","journal-title":"Clin Exp Med"},{"key":"578_CR6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871\u201390.","journal-title":"Cell"},{"key":"578_CR7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00132746","volume":"10","author":"MJ Duffy","year":"1992","unstructured":"Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clinical & experimental metastasis. 1992;10:145\u201355.","journal-title":"Clinical & experimental metastasis"},{"key":"578_CR8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52\u201367.","journal-title":"Cell"},{"key":"578_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","volume":"278","author":"C Gialeli","year":"2011","unstructured":"Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278:16\u201327.","journal-title":"FEBS J"},{"key":"578_CR10","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450\u201364.","journal-title":"Nat Med"},{"key":"578_CR11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm.2537","volume":"17","author":"SM Weis","year":"2011","unstructured":"Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17:1359\u201370.","journal-title":"Nat Med"},{"key":"578_CR12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1083\/jcb.201205169","volume":"199","author":"N Reymond","year":"2012","unstructured":"Reymond N, et al. Cdc42 promotes transendothelial migration of cancer cells through beta1 integrin. J Cell Biol. 2012;199:653\u201368.","journal-title":"J Cell Biol"},{"key":"578_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0002-9440(10)65628-3","volume":"153","author":"KJ Luzzi","year":"1998","unstructured":"Luzzi KJ, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153:865\u201373.","journal-title":"Am J Pathol"},{"key":"578_CR14","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.bbamcr.2013.06.026","volume":"1833","author":"P Paoli","year":"2013","unstructured":"Paoli P, Giannoni E, Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochim Biophys Acta. 2013;1833:3481\u201398.","journal-title":"Biochim Biophys Acta"},{"key":"578_CR15","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/nature02765","volume":"430","author":"S Douma","year":"2004","unstructured":"Douma S, et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature. 2004;430:1034\u20139.","journal-title":"Nature"},{"key":"578_CR16","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.1238856","volume":"341","author":"K Weiskopf","year":"2013","unstructured":"Weiskopf K, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science (New York, N.Y.). 2013;341:88\u201391.","journal-title":"Science (New York, N.Y.)"},{"key":"578_CR17","doi-asserted-by":"crossref","first-page":"107969","DOI":"10.1155\/2011\/107969","volume":"2011","author":"G Maccauro","year":"2011","unstructured":"Maccauro G, et al. Physiopathology of spine metastasis. International journal of surgical oncology. 2011;2011:107969.","journal-title":"International journal of surgical oncology"},{"key":"578_CR18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ana.410030107","volume":"3","author":"RW Gilbert","year":"1978","unstructured":"Gilbert RW, Kim JH, Posner JB. Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol. 1978;3:40\u201351.","journal-title":"Ann Neurol"},{"key":"578_CR19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5603\/NMR.2013.0037","volume":"16","author":"VR Kakhki","year":"2013","unstructured":"Kakhki VR, Anvari K, Sadeghi R, Mahmoudian AS, Torabian-Kakhki M. Pattern and distribution of bone metastases in common malignant tumors. Nuclear medicine review Central & Eastern Europe. 2013;16:66\u20139.","journal-title":"Nuclear medicine review Central & Eastern Europe"},{"key":"578_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.canep.2017.04.003","volume":"48","author":"JR Robinson","year":"2017","unstructured":"Robinson JR, Newcomb PA, Hardikar S, Cohen SA, Phipps AI. Stage IV colorectal cancer primary site and patterns of distant metastasis. Cancer Epidemiol. 2017;48:92\u20135.","journal-title":"Cancer Epidemiol"},{"key":"578_CR21","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/jcb.10522","volume":"89","author":"YX Sun","year":"2003","unstructured":"Sun YX, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem. 2003;89:462\u201373.","journal-title":"J Cell Biochem"},{"key":"578_CR22","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-09-2329","volume":"16","author":"BA Teicher","year":"2010","unstructured":"Teicher BA, Fricker SP. CXCL12 (SDF-1)\/CXCR4 pathway in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010;16:2927\u201331.","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"578_CR23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/pros.20500","volume":"67","author":"YX Sun","year":"2007","unstructured":"Sun YX, et al. Expression and activation of alpha v beta 3 integrins by SDF-1\/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 2007;67:61\u201373.","journal-title":"Prostate"},{"key":"578_CR24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature11926","volume":"495","author":"A Greenbaum","year":"2013","unstructured":"Greenbaum A, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. Nature. 2013;495:227\u201330.","journal-title":"Nature"},{"key":"578_CR25","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ccell.2015.05.002","volume":"27","author":"LA Pitt","year":"2015","unstructured":"Pitt LA, et al. CXCL12-producing vascular endothelial niches control acute T cell leukemia maintenance. Cancer Cell. 2015;27:755\u201368.","journal-title":"Cancer Cell"},{"key":"578_CR26","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2010.09.016","volume":"48","author":"JG Schneider","year":"2011","unstructured":"Schneider JG, Amend SR, Weilbaecher KN. Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone. 2011;48:54\u201365.","journal-title":"Bone"},{"key":"578_CR27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/jcb.21835","volume":"105","author":"Y Shiozawa","year":"2008","unstructured":"Shiozawa Y, et al. Annexin II\/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105:370\u201380.","journal-title":"J Cell Biochem"},{"key":"578_CR28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2014.11.017","volume":"27","author":"H Wang","year":"2015","unstructured":"Wang H, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27:193\u2013210.","journal-title":"Cancer Cell"},{"key":"578_CR29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2009.05.017","volume":"16","author":"XH Zhang","year":"2009","unstructured":"Zhang XH, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16:67\u201378.","journal-title":"Cancer Cell"},{"key":"578_CR30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","volume":"2","author":"GR Mundy","year":"2002","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584\u201393.","journal-title":"Nat Rev Cancer"},{"key":"578_CR31","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/nrendo.2010.227","volume":"7","author":"LJ Suva","year":"2011","unstructured":"Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208\u201318.","journal-title":"Nat Rev Endocrinol"},{"key":"578_CR32","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588\u201394.","journal-title":"Cancer"},{"key":"578_CR33","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","volume":"180","author":"MP Roudier","year":"2008","unstructured":"Roudier MP, et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol. 2008;180:1154\u201360.","journal-title":"J Urol"},{"key":"578_CR34","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","volume":"27","author":"GD Roodman","year":"1999","unstructured":"Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27:1229\u201341.","journal-title":"Exp Hematol"},{"key":"578_CR35","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.2528207","volume":"245","author":"HC Blair","year":"1989","unstructured":"Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science (New York, N.Y.). 1989;245:855\u20137.","journal-title":"Science (New York, N.Y.)"},{"key":"578_CR36","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1084\/jem.173.5.1291","volume":"173","author":"H Kodama","year":"1991","unstructured":"Kodama H, Nose M, Niida S, Yamasaki A. Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 1991;173:1291\u20134.","journal-title":"J Exp Med"},{"key":"578_CR37","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"578_CR38","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1210\/endo.142.4.8070","volume":"142","author":"T Ikeda","year":"2001","unstructured":"Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology. 2001;142:1419\u201326.","journal-title":"Endocrinology"},{"key":"578_CR39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309\u201319.","journal-title":"Cell"},{"key":"578_CR40","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","volume":"192","author":"H Min","year":"2000","unstructured":"Min H, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463\u201374.","journal-title":"J Exp Med"},{"key":"578_CR41","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","volume":"247","author":"A Mizuno","year":"1998","unstructured":"Mizuno A, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin. Biochem Biophys Res Commun. 1998;247:610\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"578_CR42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-4644(1998)72:30\/31+<73::AID-JCB11>3.0.CO;2-L","volume":"30-31","author":"JE Aubin","year":"1998","unstructured":"Aubin JE. Bone stem cells. J Cell Biochem Suppl. 1998;30-31:73\u201382.","journal-title":"J Cell Biochem Suppl"},{"key":"578_CR43","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00007632-200208151-00002","volume":"27","author":"JM Wozney","year":"2002","unstructured":"Wozney JM. Overview of bone morphogenetic proteins. Spine. 2002;27:S2\u20138.","journal-title":"Spine"},{"key":"578_CR44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1010015309973","volume":"2","author":"GR Mundy","year":"2001","unstructured":"Mundy GR, et al. Growth regulatory factors and bone. Rev Endocr Metab Disord. 2001;2:105\u201315.","journal-title":"Rev Endocr Metab Disord"},{"key":"578_CR45","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1471-4914(02)02340-7","volume":"8","author":"X Yang","year":"2002","unstructured":"Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects. Trends Mol Med. 2002;8:340\u20135.","journal-title":"Trends Mol Med"},{"key":"578_CR46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1210\/edrv-14-4-424","volume":"14","author":"GS Stein","year":"1993","unstructured":"Stein GS, Lian JB. Molecular mechanisms mediating proliferation\/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr Rev. 1993;14:424\u201342.","journal-title":"Endocr Rev"},{"key":"578_CR47","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","volume":"26","author":"LF Bonewald","year":"2011","unstructured":"Bonewald LF. The amazing osteocyte. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2011;26:229\u201338.","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"578_CR48","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bonekey.2015.122","volume":"4","author":"G David Roodman","year":"2015","unstructured":"David Roodman G, Silbermann R. Mechanisms of osteolytic and osteoblastic skeletal lesions. BoneKEy reports. 2015;4:753.","journal-title":"BoneKEy reports"},{"key":"578_CR49","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1158\/0008-5472.CAN-14-2493","volume":"75","author":"JL Sottnik","year":"2015","unstructured":"Sottnik JL, Dai J, Zhang H, Campbell B, Keller ET. Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases. Cancer Res. 2015;75:2151\u20138.","journal-title":"Cancer Res"},{"key":"578_CR50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/leu.2011.381","volume":"26","author":"N Giuliani","year":"2012","unstructured":"Giuliani N, et al. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. Leukemia. 2012;26:1391\u2013401.","journal-title":"Leukemia"},{"key":"578_CR51","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/SPC.0000000000000090","volume":"8","author":"J Delgado-Calle","year":"2014","unstructured":"Delgado-Calle J, Bellido T, Roodman GD. Role of osteocytes in multiple myeloma bone disease. Current opinion in supportive and palliative care. 2014;8:407\u201313.","journal-title":"Current opinion in supportive and palliative care"},{"key":"578_CR52","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10555-006-9029-8","volume":"25","author":"VV Glinsky","year":"2006","unstructured":"Glinsky VV. Intravascular cell-to-cell adhesive interactions and bone metastasis. Cancer Metastasis Rev. 2006;25:531\u201340.","journal-title":"Cancer Metastasis Rev"},{"key":"578_CR53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1022995403081","volume":"20","author":"AM Mastro","year":"2003","unstructured":"Mastro AM, Gay CV, Welch DR. The skeleton as a unique environment for breast cancer cells. Clinical & experimental metastasis. 2003;20:275\u201384.","journal-title":"Clinical & experimental metastasis"},{"key":"578_CR54","first-page":"742","volume":"4","author":"K Raymaekers","year":"2015","unstructured":"Raymaekers K, Stegen S, van Gastel N, Carmeliet G. The vasculature: a vessel for bone metastasis. BoneKEy reports. 2015;4:742.","journal-title":"BoneKEy reports"},{"key":"578_CR55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-007-9109-4","volume":"27","author":"KM Bussard","year":"2008","unstructured":"Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27:41\u201355.","journal-title":"Cancer Metastasis Rev"},{"key":"578_CR56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10555-014-9494-4","volume":"33","author":"LM Cook","year":"2014","unstructured":"Cook LM, Shay G, Araujo A, Lynch CC. Integrating new discoveries into the \"vicious cycle\" paradigm of prostate to bone metastases. Cancer Metastasis Rev. 2014;33:511\u201325.","journal-title":"Cancer Metastasis Rev"},{"key":"578_CR57","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","volume":"104","author":"S Colucci","year":"2004","unstructured":"Colucci S, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction. Blood. 2004;104:3722\u201330.","journal-title":"Blood"},{"key":"578_CR58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1096\/fj.04-1823fje","volume":"19","author":"I Roato","year":"2005","unstructured":"Roato I, et al. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005;19:228\u201330.","journal-title":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology"},{"key":"578_CR59","first-page":"143526","volume":"2015","author":"L D'Amico","year":"2015","unstructured":"D'Amico L, Roato I. The impact of immune system in regulating bone metastasis formation by Osteotropic tumors. J Immunol Res. 2015;2015:143526.","journal-title":"J Immunol Res"},{"key":"578_CR60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","volume":"172","author":"S Kusmartsev","year":"2004","unstructured":"Kusmartsev S, Nefedova Y, Yoder D, Gabrilovich DI. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. Journal of immunology (Baltimore, Md. : 1950). 2004;172:989\u201399.","journal-title":"Journal of immunology (Baltimore, Md. : 1950)"},{"key":"578_CR61","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.4049\/jimmunol.170.10.5064","volume":"170","author":"Y Liu","year":"2003","unstructured":"Liu Y, et al. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. Journal of immunology (Baltimore, Md. : 1950). 2003;170:5064\u201374.","journal-title":"Journal of immunology (Baltimore, Md. : 1950)"},{"key":"578_CR62","doi-asserted-by":"crossref","first-page":"689","DOI":"10.4049\/jimmunol.168.2.689","volume":"168","author":"A Mazzoni","year":"2002","unstructured":"Mazzoni A, et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. Journal of immunology (Baltimore, Md. : 1950). 2002;168:689\u201395.","journal-title":"Journal of immunology (Baltimore, Md. : 1950)"},{"key":"578_CR63","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1158\/0008-5472.CAN-11-3795","volume":"72","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, et al. Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res. 2012;72:2589\u201399.","journal-title":"Cancer Res"},{"key":"578_CR64","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/eji.201343875","volume":"44","author":"G Bian","year":"2014","unstructured":"Bian G, Zhao WY. IL-17, an important prognostic factor and potential therapeutic target for breast cancer? Eur J Immunol. 2014;44:604\u20135.","journal-title":"Eur J Immunol"},{"key":"578_CR65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fendo.2016.00090","volume":"7","author":"EV Morris","year":"2016","unstructured":"Morris EV, Edwards CM. Bone marrow adipose tissue: a new player in cancer metastasis to bone. Front Endocrinol. 2016;7:90.","journal-title":"Front Endocrinol"},{"key":"578_CR66","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.18632\/oncotarget.1482","volume":"4","author":"MK Herroon","year":"2013","unstructured":"Herroon MK, et al. Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms. Oncotarget. 2013;4:2108\u201323.","journal-title":"Oncotarget"},{"key":"578_CR67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.neo.2015.11.005","volume":"17","author":"ZS Templeton","year":"2015","unstructured":"Templeton ZS, et al. Breast Cancer Cell Colonization of the Human Bone Marrow Adipose Tissue Niche. Neoplasia (New York, N.Y.). 2015;17:849\u201361.","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"578_CR68","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/sj.leu.2404658","volume":"21","author":"J Caers","year":"2007","unstructured":"Caers J, et al. Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia. 2007;21:1580\u20134.","journal-title":"Leukemia"},{"key":"578_CR69","first-page":"65","volume":"10","author":"M Jourdan","year":"1999","unstructured":"Jourdan M, et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999;10:65\u201370.","journal-title":"Eur Cytokine Netw"},{"key":"578_CR70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1006\/cbir.2000.0497","volume":"24","author":"K Gado","year":"2000","unstructured":"Gado K, Domjan G, Hegyesi H, Falus A. Role of INTERLEUKIN-6 in the pathogenesis of multiple myeloma. Cell Biol Int. 2000;24:195\u2013209.","journal-title":"Cell Biol Int"},{"key":"578_CR71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijc.23422","volume":"123","author":"MP Valta","year":"2008","unstructured":"Valta MP, et al. FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer. 2008;123:22\u201331.","journal-title":"Int J Cancer"},{"key":"578_CR72","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1593\/neo.91836","volume":"12","author":"C Morrissey","year":"2010","unstructured":"Morrissey C, Brown LG, Pitts TE, Vessella RL, Corey E. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment. Neoplasia (New York, N.Y.). 2010;12:192\u2013205.","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"578_CR73","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1677\/erc.1.00535","volume":"11","author":"B Kwabi-Addo","year":"2004","unstructured":"Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11:709\u201324.","journal-title":"Endocr Relat Cancer"},{"key":"578_CR74","doi-asserted-by":"crossref","unstructured":"Mohan, S. Baylink, D.J. Bone growth factors. Clinical orthopaedics and related research, 30\u201348 (1991).","DOI":"10.1097\/00003086-199102000-00004"},{"key":"578_CR75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2015.10.005","volume":"99","author":"LE Cole","year":"2016","unstructured":"Cole LE, Vargo-Gogola T, Roeder RK. Targeted delivery to bone and mineral deposits using bisphosphonate ligands. Adv Drug Deliv Rev. 2016;99:12\u201327.","journal-title":"Adv Drug Deliv Rev"},{"issue":"Suppl 2","key":"578_CR76","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","volume":"119","author":"FH Glorieux","year":"2007","unstructured":"Glorieux FH. Experience with bisphosphonates in osteogenesis imperfecta. Pediatrics. 2007;119(Suppl 2):S163\u20135.","journal-title":"Pediatrics"},{"key":"578_CR77","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032\u201345.","journal-title":"Mayo Clin Proc"},{"key":"578_CR78","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","volume":"95","author":"NB Watts","year":"2010","unstructured":"Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010;95:1555\u201365.","journal-title":"J Clin Endocrinol Metab"},{"key":"578_CR79","first-page":"4753170","volume":"2016","author":"SM Kim","year":"2016","unstructured":"Kim SM, et al. Atypical complete femoral fractures associated with bisphosphonate use or not associated with bisphosphonate use: is there a difference? Biomed Res Int. 2016;2016:4753170.","journal-title":"Biomed Res Int"},{"key":"578_CR80","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2165\/11585470-000000000-00000","volume":"71","author":"EM Lewiecki","year":"2011","unstructured":"Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 2011;71:791\u2013814.","journal-title":"Drugs"},{"key":"578_CR81","doi-asserted-by":"crossref","unstructured":"Nadar RA, et al. Bisphosphonate-functionalized imaging agents, anti-tumor agents and Nanocarriers for treatment of bone cancer. Advanced healthcare materials. 2017;","DOI":"10.1002\/adhm.201601119"},{"key":"578_CR82","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1021\/la703381h","volume":"24","author":"M Iafisco","year":"2008","unstructured":"Iafisco M, et al. Adsorption and conformational change of myoglobin on biomimetic hydroxyapatite nanocrystals functionalized with alendronate. Langmuir : the ACS journal of surfaces and colloids. 2008;24:4924\u201330.","journal-title":"Langmuir : the ACS journal of surfaces and colloids"},{"key":"578_CR83","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/jbmr.5650091206","volume":"9","author":"E Beek van","year":"1994","unstructured":"van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 1994;9:1875\u201382.","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"578_CR84","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino FH, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20\u201333.","journal-title":"Bone"},{"key":"578_CR85","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879\u201382.","journal-title":"J Natl Cancer Inst"},{"key":"578_CR86","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.coph.2006.03.005","volume":"6","author":"FP Coxon","year":"2006","unstructured":"Coxon FP, Thompson K, Rogers MJ. Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol. 2006;6:307\u201312.","journal-title":"Curr Opin Pharmacol"},{"key":"578_CR87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1677\/erc.1.01094","volume":"13","author":"M Caraglia","year":"2006","unstructured":"Caraglia M, et al. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006;13:7\u201326.","journal-title":"Endocr Relat Cancer"},{"key":"578_CR88","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (London, England). 2011;377:813\u201322.","journal-title":"Lancet (London, England)"},{"key":"578_CR89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","volume":"11","author":"DL Lacey","year":"2012","unstructured":"Lacey DL, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"578_CR90","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","volume":"24","author":"PJ Kostenuik","year":"2009","unstructured":"Kostenuik PJ, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2009;24:182\u201395.","journal-title":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research"},{"key":"578_CR91","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165\u201376.","journal-title":"Cell"},{"key":"578_CR92","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0090-4295(00)01122-5","volume":"57","author":"JM Brown","year":"2001","unstructured":"Brown JM, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology. 2001;57:611\u20136.","journal-title":"Urology"},{"key":"578_CR93","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","volume":"100","author":"N Giuliani","year":"2002","unstructured":"Giuliani N, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood. 2002;100:4615\u201321.","journal-title":"Blood"},{"key":"578_CR94","first-page":"4038","volume":"61","author":"NM Luger","year":"2001","unstructured":"Luger NM, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 2001;61:4038\u201347.","journal-title":"Cancer Res"},{"key":"578_CR95","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10585-006-9026-x","volume":"23","author":"MP Roudier","year":"2006","unstructured":"Roudier MP, Bain SD, Dougall WC. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. Clinical & experimental metastasis. 2006;23:167\u201375.","journal-title":"Clinical & experimental metastasis"},{"key":"578_CR96","first-page":"2572","volume":"61","author":"BO Oyajobi","year":"2001","unstructured":"Oyajobi BO, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572\u20138.","journal-title":"Cancer Res"},{"key":"578_CR97","doi-asserted-by":"crossref","unstructured":"Wong M, Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast cancer (Dove Medical Press). 2011;3(35\u201360)","DOI":"10.2147\/BCTT.S6655"},{"key":"578_CR98","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/SPC.0b013e328355e082","volume":"6","author":"S Vengalil","year":"2012","unstructured":"Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Current opinion in supportive and palliative care. 2012;6:310\u20135.","journal-title":"Current opinion in supportive and palliative care"},{"key":"578_CR99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/PPO.0b013e318282479b","volume":"19","author":"D Brady","year":"2013","unstructured":"Brady D, Parker CC, O'Sullivan JM. Bone-targeting radiopharmaceuticals including radium-223. Cancer journal (Sudbury, Mass.). 2013;19:71\u20138.","journal-title":"Cancer journal (Sudbury, Mass.)"},{"key":"578_CR100","first-page":"235","volume":"5","author":"J Longo","year":"2013","unstructured":"Longo J, Lutz S, Johnstone C. Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases. Cancer Manag Res. 2013;5:235\u201342.","journal-title":"Cancer Manag Res"},{"key":"578_CR101","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nrurol.2015.90","volume":"12","author":"JJ Body","year":"2015","unstructured":"Body JJ, Casimiro S, Costa L. Targeting bone metastases in prostate cancer: improving clinical outcome. Nature reviews Urology. 2015;12:340\u201356.","journal-title":"Nature reviews Urology"},{"key":"578_CR102","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213\u201323.","journal-title":"N Engl J Med"},{"key":"578_CR103","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1097\/RLU.0000000000000290","volume":"38","author":"H Jadvar","year":"2013","unstructured":"Jadvar H, Quinn DI. Targeted alpha-particle therapy of bone metastases in prostate cancer. Clin Nucl Med. 2013;38:966\u201371.","journal-title":"Clin Nucl Med"},{"key":"578_CR104","unstructured":"Autio KA, Morris MJ. Targeting bone physiology for the treatment of metastatic prostate cancer. Clinical advances in hematology & oncology:H&O. 2013;11:134\u201343."},{"key":"578_CR105","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. The Lancet Oncology. 2007;8:587\u201394.","journal-title":"The Lancet Oncology"},{"key":"578_CR106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","volume":"168","author":"C Huggins","year":"2002","unstructured":"Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol. 2002;168:9\u201312.","journal-title":"J Urol"},{"key":"578_CR107","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4103\/1008-682X.151390","volume":"17","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Gray PJ. From bench to bedside: bipolar androgen therapy in a pilot clinical study. Asian journal of andrology. 2015;17:767\u20138.","journal-title":"Asian journal of andrology"},{"key":"578_CR108","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","volume":"8","author":"B Seruga","year":"2011","unstructured":"Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011;8:12\u201323.","journal-title":"Nat Rev Clin Oncol"},{"key":"578_CR109","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","volume":"31","author":"L Bubendorf","year":"2000","unstructured":"Bubendorf L, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 2000;31:578\u201383.","journal-title":"Hum Pathol"},{"key":"578_CR110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-8722-5-35","volume":"5","author":"X Huang","year":"2012","unstructured":"Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol. 2012;5:35.","journal-title":"J Hematol Oncol"},{"key":"578_CR111","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ncpuro1237","volume":"5","author":"AH Reid","year":"2008","unstructured":"Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol. 2008;5:610\u201320.","journal-title":"Nat Clin Pract Urol"},{"key":"578_CR112","first-page":"235","volume":"7","author":"J El-Amm","year":"2013","unstructured":"El-Amm J, Patel N, Freeman A, Aragon-Ching JB. Metastatic castration-resistant prostate cancer: critical review of enzalutamide. Clinical Medicine Insights Oncology. 2013;7:235\u201345.","journal-title":"Clinical Medicine Insights Oncology"},{"key":"578_CR113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W","volume":"193","author":"A Mantalaris","year":"2001","unstructured":"Mantalaris A, et al. Localization of androgen receptor expression in human bone marrow. J Pathol. 2001;193:361\u20136.","journal-title":"J Pathol"},{"key":"578_CR114","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502\u201312.","journal-title":"N Engl J Med"},{"key":"578_CR115","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet (London, England). 2016;387:1163\u201377.","journal-title":"Lancet (London, England)"},{"key":"578_CR116","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono de","year":"2010","unstructured":"de Bono JS, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376:1147\u201354.","journal-title":"Lancet (London, England)"},{"key":"578_CR117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm3010001","volume":"3","author":"BT Li","year":"2014","unstructured":"Li BT, Wong MH, Pavlakis N. Treatment and prevention of bone metastases from breast cancer: a comprehensive review of evidence for clinical practice. Journal of clinical medicine. 2014;3:1\u201324.","journal-title":"Journal of clinical medicine"},{"key":"578_CR118","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdp261","volume":"20","author":"S Beslija","year":"2009","unstructured":"Beslija S, et al. Third consensus on medical treatment of metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2009;20:1771\u201385.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology"},{"key":"578_CR119","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411\u201322.","journal-title":"N Engl J Med"},{"key":"578_CR120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.4103\/0970-1591.191240","volume":"32","author":"SF Slovin","year":"2016","unstructured":"Slovin SF. Immunotherapy in metastatic prostate cancer. Indian journal of urology : IJU : journal of the Urological Society of India. 2016;32:271\u20136.","journal-title":"Indian journal of urology : IJU : journal of the Urological Society of India"},{"key":"578_CR121","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11864-016-0433-1","volume":"17","author":"MB Stephenson","year":"2016","unstructured":"Stephenson MB, Glaenzer B, Malamis A. Percutaneous minimally invasive techniques in the treatment of spinal metastases. Curr Treat Options in Oncol. 2016;17:56.","journal-title":"Curr Treat Options in Oncol"},{"key":"578_CR122","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3174\/ajnr.A4127","volume":"35","author":"M Dohm","year":"2014","unstructured":"Dohm M, Black CM, Dacre A, Tillman JB, Fueredi G. A randomized trial comparing balloon kyphoplasty and vertebroplasty for vertebral compression fractures due to osteoporosis. AJNR Am J Neuroradiol. 2014;35:2227\u201336.","journal-title":"AJNR Am J Neuroradiol"},{"key":"578_CR123","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1097\/00002508-200009001-00006","volume":"16","author":"RJ Mannion","year":"2000","unstructured":"Mannion RJ, Woolf CJ. Pain mechanisms and management: a central perspective. Clin J Pain. 2000;16:S144\u201356.","journal-title":"Clin J Pain"},{"key":"578_CR124","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0360-3016(02)04147-0","volume":"55","author":"JS Wu","year":"2003","unstructured":"Wu JS, Wong R, Johnston M, Bezjak A, Whelan T. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys. 2003;55:594\u2013605.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"578_CR125","doi-asserted-by":"crossref","unstructured":"Sze WM, Shelley M, Held I, Mason M. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy - a systematic review of the randomised trials. The Cochrane database of systematic reviews, Cd004721. 2004;","DOI":"10.1016\/S0936-6555(03)00113-4"},{"key":"578_CR126","doi-asserted-by":"crossref","unstructured":"Chow, E. et al. Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical oncology (Royal College of Radiologists (Great Britain)) 24, 112\u2013124 (2012).","DOI":"10.1016\/j.clon.2011.11.004"},{"key":"578_CR127","doi-asserted-by":"crossref","first-page":"vi106","DOI":"10.1093\/annonc\/mdt208","volume":"6","author":"A Horwich","year":"2013","unstructured":"Horwich A, Parker C, de Reijke T, Kataja V. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology 24 Suppl. 2013;6:vi106\u201314.","journal-title":"Annals of oncology : official journal of the European Society for Medical Oncology 24 Suppl"},{"key":"578_CR128","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00007632-200102010-00016","volume":"26","author":"K Tomita","year":"2001","unstructured":"Tomita K, et al. Surgical strategy for spinal metastases. Spine. 2001;26:298\u2013306.","journal-title":"Spine"},{"key":"578_CR129","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/medicina46050045","volume":"46","author":"V Toliusis","year":"2010","unstructured":"Toliusis V, Kalesinskas RJ, Kiudelis M, Maleckas A, Griksas M. Surgical treatment of metastatic tumors of the femur. Medicina (Kaunas, Lithuania). 2010;46:323\u20138.","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"578_CR130","doi-asserted-by":"crossref","unstructured":"Ward, W.G., Holsenbeck, S., Dorey, F.J., Spang, J. Howe, D. Metastatic disease of the femur: surgical treatment. Clinical orthopaedics and related research, S230\u2013S244 (2003).","DOI":"10.1097\/01.blo.0000093849.72468.82"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-017-0578-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T19:54:26Z","timestamp":1692906866000},"score":1,"resource":{"primary":{"URL":"http:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-017-0578-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1186\/s13046-017-0578-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]},"article-number":"108"}}